SP3 Transcription Factor
A member of the Sp/KLF family of transcription factors involved in gene regulation, cell cycle control, and development.
Gene Information Card
| Symbol | SP3 |
|---|---|
| Full Name | Sp3 transcription factor |
| Gene Type | protein-coding |
| Chromosomal Location | 2q31.1 |
| NCBI Gene ID | 6670 ncbi.nlm.nih.gov/gene/6670 |
| Ensembl ID | ENSG00000172845 |
| UniProt ID | Q02447 |
| OMIM ID | 601804 |
| HGNC ID | 11209 |
| Aliases | SPR-2, FLJ16417, MGC126851 |
Description
SP3 (Sp3 transcription factor) is a protein-coding gene that belongs to the Sp/KLF family of transcription factors. It binds to GC-rich promoter sequences and regulates the expression of a wide variety of genes involved in cell cycle progression, differentiation, and apoptosis. SP3 can function as both an activator and repressor of transcription, depending on the cellular context and post-translational modifications.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Colorectal cancer | SP3 overexpression may promote tumor progression by regulating genes involved in cell proliferation and invasion. | PMID: 21573172 |
| Gastric cancer | SP3 expression is upregulated and associated with poor prognosis; may regulate CDH1 (E-cadherin) expression. | PMID: 23546790 |
| Prostate cancer | SP3 modulates androgen receptor signaling and contributes to hormone-independent growth. | PMID: 19351800 |
| Hepatocellular carcinoma | SP3 is overexpressed and correlates with metastasis; regulates MMP-9 expression. | PMID: 22492982 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 32.5 | High |
| Lymph node | 25.1 | High |
| Spleen | 22.8 | High |
| Bone marrow | 20.3 | High |
| Brain | 12.4 | Medium |
| Liver | 8.7 | Medium |
| Heart | 6.2 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK 293 | 28.5 | Embryonic kidney; high expression |
| HeLa | 22.1 | Cervical carcinoma; high expression |
| K562 | 19.8 | Leukemia; moderate expression |
| MCF7 | 15.3 | Breast cancer; moderate expression |
| A549 | 12.0 | Lung cancer; moderate expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1075C>T (p.Arg359Trp) | missense | <0.01% | Unknown; rare variant in population databases |
| c.1234G>A (p.Gly412Ser) | missense | <0.01% | Unknown; rare variant in population databases |
| c.1462_1463insA (p.Thr488Asnfs*12) | frameshift | <0.01% | Predicted loss of function |
Mutation functional classification
Loss of Function (LOF)
Frameshift and nonsense mutations that truncate the protein are predicted to cause loss of function, impairing DNA binding and transcriptional activity.
Gain of Function (GOF)
No well-characterized gain-of-function mutations have been reported in SP3.
Dominant Negative (DN)
Some missense mutations in the DNA-binding domain may act in a dominant-negative manner by competing with wild-type SP3 for promoter binding.
View complete mutation data：
Gene Ontology (GO)
| • DNA-binding transcription factor activity (GO:0003700) | • RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978) |
| • chromatin binding (GO:0003682) | • regulation of transcription by RNA polymerase II (GO:0006357) |
| • positive regulation of transcription by RNA polymerase II (GO:0045944) | • negative regulation of transcription by RNA polymerase II (GO:0000122) |
| • cell differentiation (GO:0030154) | • apoptotic process (GO:0006915) |
Pathways
• Sp/KLF family signaling
• TGF-beta signaling pathway (via SMAD interaction)
• p53 signaling pathway (regulation of CDKN1A/p21)
Protein Summary
SP3 is a 781-amino acid protein containing a glutamine-rich activation domain and three C2H2-type zinc fingers that mediate sequence-specific DNA binding to GC-rich motifs. It is ubiquitously expressed and shuttles between the nucleus and cytoplasm. Post-translational modifications including acetylation, phosphorylation, and sumoylation modulate its transcriptional activity. SP3 can compete with Sp1 for binding to overlapping promoter sites, leading to either activation or repression of target genes.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CASP3 Knockout HEK293 Cell Line | EDJ-KQ632 | Human | 836 | Details Get a Quote |
| DUSP3 Knockout HEK293 Cell Line | EDJ-KQ643 | Human | 1845 | Details Get a Quote |
| USP32 Knockout HEK293 Cell Line | EDJ-KQ2225 | Human | 84669 | Details Get a Quote |
| USP33 Knockout HEK293 Cell Line | EDJ-KQ2412 | Human | 23032 | Details Get a Quote |
| SP3 Knockout HEK293 Cell Line | EDJ-KQ5827 | Human | 6670 | Details Get a Quote |
| USP34 Knockout HEK293 Cell Line | EDJ-KQ6722 | Human | 9736 | Details Get a Quote |
| USP3 Knockout HEK293 Cell Line | EDJ-KQ6845 | Human | 9960 | Details Get a Quote |
| CRISP3 Knockout HEK293 Cell Line | EDJ-KQ7005 | Human | 10321 | Details Get a Quote |
| MISP3 Knockout HEK293 Cell Line | EDJ-KQ7414 | Human | 113230 | Details Get a Quote |
| USP38 Knockout HEK293 Cell Line | EDJ-KQ10144 | Human | 84640 | Details Get a Quote |
| USP30 Knockout HEK293 Cell Line | EDJ-KQ10187 | Human | 84749 | Details Get a Quote |
| DISP3 Knockout HEK293 Cell Line | EDJ-KQ12388 | Human | 57540 | Details Get a Quote |
| OOSP3 Knockout HEK293 Cell Line | EDJ-KQ14562 | Human | 112577461 | Details Get a Quote |
| USP31 Knockout HEK293 Cell Line | EDJ-KQ16078 | Human | 57478 | Details Get a Quote |
| USP35 Knockout HEK293 Cell Line | EDJ-KQ16079 | Human | 57558 | Details Get a Quote |
Displaying Records 1 To 15 Of 68 Records
- 1
- 2
- Next Page »
